Abstract:The aggregation pathway of transthyretin (TTR) proceeds through rate-limiting dissociation of the tetramer (a dimer of dimers) and partial misfolding of the resulting monomer, which assembles into amyloid structures through a downhill polymerization mechanism. The structural features of the aggregation-prone monomeric intermediate are poorly understood. NMR relaxation dispersion offers a unique opportunity to characterize amyloidogenic intermediates when they exchange on favorable timescales with NMR-visible ground states. Here we use NMR to characterize the structure and conformational dynamics of the monomeric F87E mutant of human TTR. Chemical shifts derived from analysis of multinuclear relaxation dispersion data provide insights into the structure of a low-lying excited state that exchanges with the ground state of the F87E monomer at a rate of 3800 s-1. Disruption of the subunit interfaces of the TTR tetramer leads to destabilization of edge strands in both β-sheets of the F87E monomer. Conformational fluctuations are propagated through the entire hydrogen bonding network of the DAGH β-sheet, from the inner β-strand H, which forms the strong dimer-dimer interface in the TTR tetramer, to outer strand D which is unfolded in TTR fibrils. Fluctuations are also propagated from the AB loop in the weak dimer-dimer interface to the EF helix, which undergoes structural remodeling in fibrils. The conformational fluctuations in both regions are enhanced at acidic pH where amyloid formation is most favorable. The relaxation dispersion data provide insights into the conformational dynamics of the amyloidogenic state of monomeric TTR that predispose it for structural remodeling and progression to amyloid fibrils.

Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis

The conformational landscape of human transthyretin revealed by cryo-EM

Structure-based probe reveals the presence of large transthyretin aggregates in plasma of ATTR amyloidosis patients

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis

Multi-organ structural homogeneity of amyloid fibrils in ATTRv-T60A amyloidosis patients, revealed by Cryo-EM

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

ATTRv-V30M amyloid fibrils from heart and nerves exhibit structural homogeneity

Treatment of transthyretin cardiac amyloidosis

Cryo-EM confirms a common fibril fold in the heart of four patients with ATTRwt amyloidosis

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges

Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings

Human in vitro disease modeling of ATTR cardiac amyloidosis

The Transthyretin Protein and Amyloidosis – an Extraordinary Chemical Biology Platform

Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation

ATTRv-V30M Type A amyloid fibrils from heart and nerves exhibit structural homogeneity

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy